Must be able to travel to Hershey Medical Center for 12 visits
Must be diagnosed with HS for 1 year prior to study participation
Must be willing to perform self injections at home
Prior treatment of Humira or other biologics for the treatment of HS

High risk cutaneous squamous cell carcinoma
Post resection and curative intent post-operative Radiation Therapy within 2 to 6 weeks of randomization
Adequate hepatic, renal, and bone marrow function as defined in the protocol
Patients with blood cancer (hematologic malignancies) or other malignancies
Squamous cell carcinomas (SCCs) arising in non-cutaneous sites as defined in the protocol
Significant autoimmune disease that required treatment with systemic immunosuppressive treatments (including corticosteroids)
Has had prior systemic anti-cancer immunotherapy for cutaneous squamous cell carcinoma

Histologically confirmed HER2-positive primary invasive breast carcinoma
Patents must have a left ventricular ejection fraction (LVEF) within normal institutional parameters (or > 50%).
Patient must not have a history of any prior (ipsilateral or contralateral) invasive breast cancer.
Patient must not have Stage IV (metastatic) breast cancer
Patient must not have T4 and/or N3 disease, including inflammatory breast cancer.
Patient must not have any prior treatment for the current breast cancer, including surgery, chemotherapy, hormonal therapy, radiation or experimental therapy.
Patient must not have a concurrent serious medical condition that would preclude completion of study therapy.

Ages 18-40
ACL Group: ACL Reconstruction surgery 9-24 months prior and approved to return to normal activities
Control group: No history of lower extremity surgery
Able to provide consent and read/write in English
No current musculoskeletal injuries
Prisoner
Pregnant person
Below age 18 or above Age 40
Unable to provide consent or read/write in english
Unable to perform movements consistent with daily activities such as jogging, jumping, or moving from sit to stand

Patients must have undergone complete surgical resection of their
Patients must be registered to the ALCHEMIST-SCREEN (ALLIANCE
ALK positive
Patients must have completed any prior adjuvant chemotherapy or
No prior treatment with crizotinib or another ALK inhibitor.

Patient must be = 18 years of age.
Patient must have an ECOG performance status of 0-1.
Patient must have undergone initial cholecystectomy within 12 weeks prior to randomization
Patient must have histologically-confirmed T2 or T3 gallbladder cancer discovered incidentally at the time of or following routine cholecystectomy for presumed benign disease
Patient must not have any evidence of metastatic disease or inoperable loco-regional disease based on high-quality, preoperative, cross-sectional imaging (CT or MRI) of the chest, abdomen, and pelvis (C/A/P) obtained within 6 weeks prior to randomization
Women must not be pregnant or breast feeding due to the potential harm to unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used.
No radiographic evidence of distant disease (M1 disease)
No radiographic evidence of tumor invasion into multiple extrahepatic organs (T4 disease)
No radiographic evidence of distant lymph node involvement (celiac, para-aortic, para-caval lymph nodes)

Pathologically (histologically or cytologically) proven diagnosis of squamous cell carcinoma of the oral cavity
Age ≥ 18
Zubrod Performance Status 0-2 within 42 days prior to registration
Only English speaking patients (able to read and understand English) are eligible to participate as the mandatory patient reported NDII tool is only available in this language
For women of child bearing potential, negative serum or urine pregnancy test within 42 days prior to registration
Definitive clinical or radiologic evidence of regional (cervical) and/or distant metastatic disease
Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable
Patient with severe, active co-morbidity that would preclude an elective or completion neck dissection
Incomplete resection of oral cavity lesion with a positive margin; however, an excision biopsy is permitted
Actively receiving systemic cytotoxic chemotherapy, immunosuppressive, anti-monocyte or immunomodulatory therapy.

Pathologically proven diagnosis of NSCLC, with metastases (stage IV disease) present prior to registration.
Age = 18;
Zubrod Performance Status 0, 1, or 2 within 30 days prior to registration;
Adequate organ and hematologic/bone marrow function within 14 days prior to registration
Negative serum pregnancy test within one week prior to registration for females of childbearing potential
Prior bevacizumab therapy is excluded.
Clinical or radiologic evidence of new, untreated, and/or progressive brain metastases prior to registration after induction systemic therapy
Cutaneous metastasis of NSCLC;
Metastatic disease invading the esophagus, stomach, intestines, or mesenteric lymph nodes if not a candidate for surgery for these lesions;
Prior invasive malignancy (except non-melanomatous skin cancer, low or intermediate risk prostate cancer, or in situ carcinoma of breast, oral cavity, skin, or cervix) unless disease free for a minimum of one year

Women aged 18 to 49 years, inclusive,
Scheduled to undergo (within 30 days) either a) laparotomy or laparoscopy for signs and symptoms of suspected endometriosis or b) laparotomy, laparoscopy for another type of gynecologic procedure.
Willing and able to provide up to 50 mL of blood via venipuncture and comply with all other study and sample collection procedures
History of surgically determined diagnosis of endometriosis
Is in a pre-menarchal or post-menopausal state, or has been rendered surgically menopausal
Is pregnant or has an active pelvic infection
Has an active malignancy
Is known to have HIV or Hepatitis A, B or C

At least 18 years old
Subjects must have a history of primary brain tumor (including but not limited to glioblastoma (GBM), anaplastic astrocytoma (AA), anaplastic ganglioglioma (AG), and anaplastic pleomorphic xanthoastrocytoma (PXA)).
Subjects must have a BRAF-V600 mutation identified in previous tissue analysis (may be IHC or PCR based). Allowable mutations include V600E, V600K, V600R, and V600D.
Subjects must be taking dabrafenib at a dose of at least 50mg twice daily (adults only) and / or trametinib at a dose of at least 1mg daily (adults only) for at least 7 days prior to surgery as prescribed by their treating physician.
Subjects must be undergoing surgery for clinical purposes
Younger than 18 year old
Subjects who are receiving any other investigational agents or chemotherapeutic agents.

Adult 18+
Subjects with Colon Cancer or Adenoma
OR subjects undergoing colonoscopy screening
Inflammatory Bowel Disease
HIV/Hepatitis
Have had or are receiving chemotherapy or radiation
Have had surgery for your colon cancer
Cognitive Impairment

Must need cataract surgery
18 years of age and older
History of intraocular or corneal surgery
current ocular infection
serious corneal disease.

Pregnant woman
Planned delivery via C-section
Pfannenstiel ("bikini line") skin incision
Able to read and speak English fluently
Major intra-operative or post-operative complication such that clinical recommends patient should not receive non-steroidal anti-inflammatory drugs
Unplanned surgery (hysterectomy, bowel/bladder repair, cystoscopy)
Allergy or contraindication to study medication
History of opioid or other substance use disorder either before or during pregnancy
History of kidney or liver disease

Squamous or non-squamous NSCLC histology
Complete surgical resection of their NSCLC with negative margins
Surgery completed within 60 days prior to starting treatment
Small cell or large cell neuroendocrine histology
EGFR mutations and ALK re-arrangements
Prior chemotherapy, radiation therapy, or immunotherapy for lung cancer
Other active cancers
Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor

Males and females age ≥ 18 years.
Patients must have undergone complete surgical resection of their stage I non-small cell lung cancer between 4-12 weeks prior to registration.
Pathological tumor size must be 1.0 – 4.0 cm in size.
ECOG Performance Score 0-1
Baseline CT chest must be performed within 28 days of randomization
Patients with tumors that are known to harbor actionable EGFR mutations are NOT eligible.
No prior PD-1 or PD-L1 inhibitors are permitted.
No prior neo-adjuvant or adjuvant chemotherapy is permitted for this lung cancer.
Patients with a history of (non-infectious) pneumonitis that required steroids
Has active autoimmune disease that has required systemic treatment in the past 2 years.

Scheduled for breast cancer surgery
Not metastatic (stage <4)
more than 2 weeks till surgery
Receiving neoadjuvant chemotherapy or radiotherapy
Pregnant
• Engaging in systematic intense exercise training (at least 1h twice per week)

ACL tear within last 12-36 months
Full rehabilitation
autograft taken from hamstring tendon
other autografts may be considered
Recreationally active
Other major knee injury (i.e. MCL tear)

Patient must be = 18 years of age.
Patient must have undergone a radical prostatectomy (RP) and must be preregistered to Step 0 of this study at least 6 weeks after but not more than 12 weeks after their radical prostatectomy.
Patient must not have any previous treatment with androgen deprivation therapy (ADT), chemotherapy, or other physician prescribed systemic therapy for treatment of their prostate cancer.
Patient must have an ECOG performance status of 0-2.
Patient must not have pathologic evidence of pelvic lymph node involvement.
Patient must not have an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (New York Heart Association Class III and IV heart failure).

Patient has histologically-confirmed diagnosis of localized, untreated prostate cancer with high-risk features
Patient has sufficient archival tissue (at least 2 cores) available for targeted sequencing and immunohistochemistry
Patient has measurable PSA
Patient must be male and >= 18 years of age
Patient must be able to swallow pills
Patient has histology of small cell carcinoma prostate cancer. Adenocarcinoma with neuroendocrine features is allowed.
Patient has active infection requiring IV antibiotics
Patient has known additional malignancy that has a life expectancy < 10 years
Patient has distant metastatic disease beyond N1 (regional) lymph nodes on conventional baseline imaging studies within 90 days prior to signing consent

New or recurrent low-grade, non-invasive UTUC disease
Biopsy-proven disease. A concurrence of the central pathology reader will be required for eligibility.
Up to 2 biopsy-proven sites of low-grade involvement. Please contact site for tumor dimension criteria.
Karnofsky Performance Status ≥ 50%
Adequate organ function defined by baseline Lab testing
Current high-grade or muscle invasive (>pT1) urothelial carcinoma of the bladder
Carcinoma in situ (CIS) current or previous in the upper urinary tract
History of invasive T2 or higher urothelial cancer in past 2 years
Participation in another clinical study involving an investigational product within 1 month before study entry
BCG or local chemotherapy treatment in the upper urinary tract within 2 months prior to inclusion